Back to Results

Alpha Tau Medical Ltd (DRTS)

Featured in Overvalued Stocks High-Beta Stocks High-Momentum Stocks High-Beta Momentum Small-Cap Stocks

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company listed on the NASDAQ under the ticker DRTS. The company is focused on developing and commercializing Alpha DaRT, a diffusing alpha-emitters radiation therapy intended for solid tumors. Its program is being evaluated in clinical studies across several cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers, alongside additional preclinical work in mouse and human-derived tumor models. Alpha Tau Medical is headquartered in Jerusalem, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-DRTS
$8.72
-34.2% Downside
Overvalued
$14.20
7.0% Upside
Fair
Fair
—
—
—
0.0%
August 18, 2026
-21.0x
17.2x
—
1.215 B
1.131 B
1.2%
68.7%
0.1
—
57.6%
Send a message
Valuation • Fair Value

Alpha Tau Medical Ltd (NASDAQ-DRTS) Fair Value by Valuation Model

Compare the primary fair value estimate for Alpha Tau Medical Ltd (NASDAQ-DRTS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$8.72

Estimated downside of 34.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$10.55

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$7.81

Comparable-company valuation reference.

Analyst Price Target

$14.20

Analysts imply upside of 7.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Alpha Tau Medical Ltd (NASDAQ-DRTS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Alpha Tau Medical Ltd (NASDAQ-DRTS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

1.701 M

Forward revenue estimate.

EBITDA

-45.029 M

Current operating profitability reference.

EBITDA Forecast

-42.526 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Alpha Tau Medical Ltd (NASDAQ-DRTS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Alpha Tau Medical Ltd (NASDAQ-DRTS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

0.1

Lower score that deserves closer risk review.

FCF / Net Income

57.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Alpha Tau Medical Ltd (NASDAQ-DRTS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Alpha Tau Medical Ltd (NASDAQ-DRTS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 18, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Alpha Tau Medical Ltd (NASDAQ-DRTS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Alpha Tau Medical Ltd (NASDAQ-DRTS) Stock Forecast & Technical Outlook

Review Alpha Tau Medical Ltd (NASDAQ-DRTS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Alpha Tau Medical Ltd (NASDAQ-DRTS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Alpha Tau Medical Ltd (NASDAQ-DRTS) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ • Fast Investor Answers

Alpha Tau Medical Ltd (NASDAQ-DRTS) Stock FAQ

Quick answers about Alpha Tau Medical Ltd (NASDAQ-DRTS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$8.72
Estimated downside 34.2%
Valuation Rating
Overvalued
Estimated downside of 34.2%
Analyst Target
$14.20
Implied upside 7.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Alpha Tau Medical Ltd (NASDAQ-DRTS) is $8.72. This implies an estimated downside of 34.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 34.2% versus the current market price.

The available analyst price target for Alpha Tau Medical Ltd (NASDAQ-DRTS) is $14.20. The analyst target implies estimated upside of 7.0%.

The current financial health read for Alpha Tau Medical Ltd (NASDAQ-DRTS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Alpha Tau Medical Ltd (NASDAQ-DRTS) is August 18, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Alpha Tau Medical Ltd (NASDAQ-DRTS) is -21.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Alpha Tau Medical Ltd is 1.215 B.

The current enterprise value listed for Alpha Tau Medical Ltd is 1.131 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Alpha Tau Medical Ltd is NASDAQ-DRTS, and the stock is listed on NASDAQ.

Alpha Tau Medical Ltd (NASDAQ-DRTS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Alpha Tau Medical Ltd is 1.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Alpha Tau Medical Ltd is 68.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
Omnicell Inc (OMCL) Omnicell Inc (OMCL)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)